Supporting a tumor-suppressive role for H2Bub1 and providing a rational for pursuing H2Bub1-based therapeutic development in breast cancer, Prenzel et al. [33] found that specific inhibition of ERα activity by treatment with bortezomib (or Velcade) caused a global decease H2Bub1, leading to decreased expression of ERα-target genes in MCF7 breast cancer cells. The gene discussed is ESR1; the disease is breast cancer.